Physician profile

Jorge M Ramirez

Cardiovascular Disease · Glen Burnie, MD

NPI 1679589899

$6,851.58

in general payments reported to CMS, 2019-2025

43 companies · $2,409 in 2025

The $2,409 reported for 2025 was more than what 86% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$3,903.62
Education$116.00

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Aop Health US, LLC $1,055.25 2025 Rapiblyk
Amgen INC. $624.51 2019-2025 Repatha, Repatha
Boehringer Ingelheim Pharmaceuticals, INC. $475.56 2019-2025 Jardiance
Medtronic, INC. $466.65 2022-2025 Linq II, Micra
Pfizer INC. $407.57 2019-2025
E.R. Squibb & Sons, L.L.C. $362.68 2019-2025 Camzyos, Eliquis
Novartis Pharmaceuticals Corporation $325.51 2019-2025
Janssen Pharmaceuticals, INC $318.64 2019-2024 Xarelto
Medtronic Vascular, INC. $254.45 2019
Novo Nordisk INC $232.13 2023-2025 Wegovy, Ozempic
Astrazeneca Pharmaceuticals Lp $213.67 2019-2024 Brilinta
Heartflow, INC. $186.98 2024-2025
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $184.55 2019-2025 Lifevest
Abiomed $169.78 2021-2024
Amarin Pharma, INC. $157.85 2019-2020
Show all 43 companies
CompanyGeneral paymentsYearsTop products
Sanofi-Aventis U.S. LLC $154.93 2019-2024
Boston Scientific Corporation $153.68 2019-2023 Watchman
Lilly USA, LLC $112.55 2020
Philips North America LLC $100.15 2023-2025 Ambulatory Monitoring & Diagnostics Undivided, Extended Holter
Atricure, INC. $86.51 2019-2024
Preventice Services, LLC $81.23 2019
Medicomp INC $58.37 2020-2025 Telepatch Cardiac Monitor
Abbott Laboratories $54.77 2019
Kowa Pharmaceuticals America, INC. $51.04 2019-2020
Kiniksa Pharmaceuticals International, Plc $47.19 2024 Arcalyst
Astellas Pharma US INC $46.86 2019
Esperion Therapeutics, INC. $46.77 2024-2025 Nexletol
Biosense Webster, INC. $44.19 2025 Carto 3
Kiniksa Pharmaceuticals, Ltd. $41.68 2023 Arcalyst
Bridgebio Pharma, INC. $38.64 2025 Attruby
Merck Sharp & Dohme LLC $33.70 2021-2023 Verquvo
Lundbeck LLC $33.15 2019-2021
Scpharmaceuticals INC. $31.63 2023-2024
Irhythm Technologies, INC. $31.39 2023 Zio Xt Patch
Actelion Pharmaceuticals US, INC. $29.00 2025 Uptravi
Daiichi Sankyo INC. $25.70 2024 Injectafer
Lexicon Pharmaceuticals, INC. $22.98 2023 Inpefa
Lantheus Medical Imaging, INC. $20.70 2024
Kestra Medical Technology Services, INC. $15.97 2023 Assure Wcd
Vital Connect, INC $14.83 2024 Vitalpatch Rtm
Arbor Pharmaceuticals, INC. $14.45 2019
Gilead Sciences, INC. $12.84 2019
Regeneron Healthcare Solutions, INC. $10.90 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Jorge M Ramirez

$6,851.58

in general payments reported 2019-2025

Years
2019-2025
Top company
Aop Health US, LLC
Context
The $2,409 reported for 2025 was more than what 86% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).

https://glasscript.com/doctor/30948/jorge-m-ramirez

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.